Source comparison
Comparison: Muscle Recovery Peptides by Mechanism and Application
| Peptide | Primary Mechanism | Ideal Application | Typical Dose (2026 Research) | Dosing Frequency | Half-Life | Bottom Line Assessment ||—|—|—|—|—|—|| BPC-157 | Angiogenesis + VEGF upregulation + collagen synthesis | Acute tendon/ligament injury (first 72 ho
This comparison does not assign a generated winner or score.
- | Peptide | Primary Mechanism | Ideal Application | Typical Dose (2026 Research) | Dosing Frequency | Half-Life | Bottom Line Assessment ||—|—|—|—|—|—|| BPC-157 | Angiogenesis + VEGF upregulation + collagen synthesis | Acute tendon/ligament injury (first 72 hours) | 250–500mcg subcutaneous | Daily for 8–12 weeks | ~4 hours | Strongest evidence for soft tissue repair when administered early; no benefit if delayed >96 hours || TB-500 | Actin sequestration + cell migration + fibrosis reduction | Post-surgical recovery, chronic tendinopathy | 250–500mcg subcutaneous | Twice weekly for 8–12 weeks | ~10 days | Improves tissue quality (less scar tissue, denser collagen) but doesn't accelerate initial healing || CJC-1295/Ipamorelin | GH pulse amplification + IGF-1 elevation | Enhanced recovery in structured training + caloric surplus | 100mcg each, combined | 5x/week pre-bed | CJC: 6–8 days; Ipa: 2 hours | Reliably elevates IGF-1; hypertrophic effects depend entirely on training and nutrition.